Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis

(2013) Katrina E. Donahue et al.   ANNALS OF INTERNAL MEDICINE

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

(2012) Monika Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Lack of Head-to-head Trials and Fair Control Arms

(2012) Candice Estellat   ARCHIVES OF INTERNAL MEDICINE

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment

(2012) Teresa A Simon et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

(2011) Yusuf Yazici et al.   ANNALS OF THE RHEUMATIC DISEASES

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

(2011) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

(2011) David T. Felson et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) R. Knevel et al.   ANNALS OF THE RHEUMATIC DISEASES

State-of-the-art: rheumatoid arthritis

(2010) I. B. McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals

(2009) M. Boers   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

(2009) G R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness of tumour necrosis factor   inhibitors in combination with either methotrexate or leflunomide

(2009) A Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment

(2009) D. Aletaha et al.   ARTHRITIS AND RHEUMATISM

Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study

(2009) R. WESTHOVENS et al.   JOURNAL OF RHEUMATOLOGY

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

(2008) G Wells et al.   ANNALS OF THE RHEUMATIC DISEASES

Decreased external home help use with improved clinical status in rheumatoid arthritis: An exploratory analysis of the Abatacept in Inadequate Responders to Methotrexate (AIM) trial

(2008) Tracy Li et al.   CLINICAL THERAPEUTICS

Autoantibody production in patients treated with anti-TNF-α

(2008) Fabiola Atzeni et al.   Expert Review of Clinical Immunology

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

(2007) H K Genant et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES